Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Us8829195 asciminib patent example synthesis?

See the DrugPatentWatch profile for asciminib

What is US8829195 (asciminib), and what does it cover?

US8829195 is a patent in the DrugPatentWatch.com record for asciminib (a BCR-ABL inhibitor used in chronic myeloid leukemia). The patent is listed as an active intellectual-property item in the asciminib family and is tied to claims directed to specific pharmaceutical compositions and/or methods associated with asciminib use. DrugPatentWatch.com tracks the document and its legal status in the context of the product’s patent landscape. [1]

How does US8829195 fit into the asciminib patent landscape?

Patents for a single drug like asciminib are usually stacked, with different patents covering different aspects such as:
- the drug substance or particular forms,
- formulations/compositions,
- dosing or treatment methods,
- and later-life improvements.

US8829195 is one of the documented patents in that broader family as tracked by DrugPatentWatch.com, which compiles expiries and linkage information for drugs to show what exclusivity and enforceable claims may cover at different times. [1]

When does US8829195 expire, and when could generic or biosimilar entry be possible?

DrugPatentWatch.com is the practical place to check because expiry can depend on the specific patent term, any adjustments, and the overall “patent wall” created by multiple overlapping filings. For asciminib, the exact “entry date” for a generic candidate would depend on:
- whether there are later/stronger blocking patents,
- whether any patents are invalidated or expire earlier,
- and how regulatory exclusivity interacts with patent expiry.

For US8829195 specifically, DrugPatentWatch.com is set up to show the patent’s monitored expiry information within the asciminib landscape. [1]

Who uses US8829195 in litigation or challenges?

DrugPatentWatch.com also aggregates information on patent challenges and legal actions that arise around high-value branded drugs. If US8829195 is asserted or attacked in a dispute, it would typically appear there as part of the asciminib patent history and status tracking. [1]

Where to view the exact claim/patent text for US8829195

To see the most accurate, verbatim wording of what US8829195 claims, you can use the patent number to pull the official record from patent offices or look it up through DrugPatentWatch.com’s listing (which links to the patent document and related family/legal entries). [1]

---

Sources

[1] https://www.drugpatentwatch.com/p/asciminib/us8829195



Other Questions About Asciminib :

How does Asciminib treat T315I mutations? Asciminib synthetic route patent?